Research Article
Clinical Features, Diagnosis, Treatment, and Prognosis of Heparin-Induced Bullous Hemorrhagic Dermatosis
Table 4
Treatment and prognosis of 72 patients with HBHD.
| Parameters | ā | Result |
| Treatment | Discontinued | 44 (61.1%) | Continued | 20 (27.8%) | Unspecified | 7 (9.7%) | Dose reduction | 1 (1.4%) | Switch to other anticoagulants | 21 (29.2%) | Oral anticoagulant | 15 (20.8%) | Fondaparinux | 2 (2.8%) | Other low molecular weight heparin | 4 (5.6%) | Rechallenge | 1 (1.4%) |
| Outcome | Recovery | 67 (93.1%) | Unspecified | 5 (6.9%) | Death | 4 (5.6%) |
| Time to resolution (46)a | Days | 14 (2, 141)b |
|
|
aRepresents the number of patients out of 72 for whom information regarding this particular parameter was provided. bMedian (minimum-maximum).
|